Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for unmet medical needs. The company's product pipeline includes topical formulations for skin disorders associated with cancer therapy, treatments for Alzheimer's and other neuroinflammatory diseases, as well as solutions for inflammatory bowel diseases, asthma, allergies, and lung diseases. Additionally, Hoth Therapeutics is working on a novel peptide for COVID-19 treatment. The company generates revenue through the development and commercialization of its proprietary drug compounds and platforms, as well as through research collaborations and license agreements with leading academic and pharmaceutical institutions.

Products

• HT-001 topical formulation

• HT-KIT for mast-cell derived cancers and anaphylaxis

• HT-ALZ for Alzheimer's and neuroinflammatory diseases

• HT-003 for inflammatory bowel diseases, acne, and psoriasis

• HT-004 for asthma and allergies

• HT-006 for lung diseases from bacterial infections

• HT-002 novel peptide for COVID-19 treatment

• BioLexa Platform for eczema treatment

• HT-005 for lupus treatment